In Vitro Model for a Drug Assessment of Cytochrome P450 Family 3 Subfamily A Member 4 Substrates Using Human Induced Pluripotent Stem Cells and Genome Editing Technology

Sayaka Deguchi, Tomohiro Shintani, Kazuo Harada, Toru Okamoto, Akinori Takemura, Kazumasa Hirata, Kousei Ito, Kazuo Takayama, Hiroyuki Mizuguchi – 4 May 2021 – In drug development, a system for predicting drug metabolism and drug‐induced toxicity is necessary to ensure drug safety. Cytochrome P450 family 3 subfamily A member 4 (CYP3A4) is an important drug‐metabolizing enzyme expressed in the liver and small intestine, and predicting CYP3A4‐mediated drug metabolism and drug‐induced toxicity is essential.

Bile Salt and FGF19 Signaling in the Early Phase of Human Liver Regeneration

Kiran V.K. Koelfat, Kim M.C. Mierlo, Toine M. Lodewick, Johanne G. Bloemen, Gregory Kroft, Iakovos Amygdalos, Ulf P. Neumann, Cornelis H.C. Dejong, Peter L.M. Jansen, Steven W.M. Olde Damink, Frank G. Schaap – 4 May 2021 – The involvement of bile salt–fibroblast growth factor 19 (FGF19) signaling in human liver regeneration (LR) is not well studied. Therefore, we studied aspects of bile salt–FGF19 signaling shortly after liver resection in patients.

Hepatocellular Carcinoma Screening Process Failures in Patients with Cirrhosis

Patrick Marquardt, Po‐Hong Liu, Joshua Immergluck, Jocelyn Olivares, Ana Arroyo, Nicole E. Rich, Neehar D. Parikh, Adam C. Yopp, Amit G. Singal – 3 May 2021 – Professional society guidelines recommend semiannual screening for hepatocellular carcinoma (HCC) in patients with cirrhosis; however, studies suggest underuse of screening in clinical practice. Our study’s aim was to characterize reasons for HCC screening underuse among patients with cirrhosis. We conducted a retrospective cohort study of patients with cirrhosis diagnosed with HCC in two large health systems from 2011 to 2019.

Subscribe to